Scaffold Searching of FDA and EMA-Approved Drugs Identifies Lead Candidates for Drug Repurposing in Alzheimer’s Disease

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource

Language: Englisch

Bibliographic citation: In: Frontiers in Chemistry (2021) 9:736509. doi: 10.3389/fchem.2021.736509

Event: Veröffentlichung

(where): Würzburg

(who): Universität Würzburg

(when): 2022

Creator: Shityakov, Sergey
Skorb, Ekaterina V.
Förster, Carola Y.
Dandekar, Thomas

DOI: 10.3389/fchem.2021.736509

URN: urn:nbn:de:bvb:20-opus-248703

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:33 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Shityakov, Sergey
Skorb, Ekaterina V.
Förster, Carola Y.
Dandekar, Thomas
Universität Würzburg

Time of origin

2022

Other Objects (12)

Repurposing FDA-approved drugs for anti-aging therapies

Repurposing FDA‐Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease

Hochschulschrift

Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus

Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans

Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer

Computational prognostic evaluation of Alzheimer’s drugs from FDA-approved database through structural conformational dynamics and drug repositioning approaches

Repurposing of approved cardiovascular drugs

Single-cell-led drug repurposing for Alzheimer’s disease

In silico repurposing of antipsychotic drugs for Alzheimer’s disease

Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells

The First FDA-Approved Antibody-Drug Conjugate

A systematic analysis of FDA-approved anticancer drugs

Repurposing FDA-approved drugs for anti-aging therapies

Repurposing FDA‐Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease

Hochschulschrift

Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus

Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans

Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer

Computational prognostic evaluation of Alzheimer’s drugs from FDA-approved database through structural conformational dynamics and drug repositioning approaches

Repurposing of approved cardiovascular drugs

Single-cell-led drug repurposing for Alzheimer’s disease

In silico repurposing of antipsychotic drugs for Alzheimer’s disease

Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells

The First FDA-Approved Antibody-Drug Conjugate

A systematic analysis of FDA-approved anticancer drugs

Repurposing FDA-approved drugs for anti-aging therapies

Repurposing FDA‐Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease

Hochschulschrift

Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus

Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans

Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer

Computational prognostic evaluation of Alzheimer’s drugs from FDA-approved database through structural conformational dynamics and drug repositioning approaches

Repurposing of approved cardiovascular drugs

Single-cell-led drug repurposing for Alzheimer’s disease

In silico repurposing of antipsychotic drugs for Alzheimer’s disease

Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells

The First FDA-Approved Antibody-Drug Conjugate

A systematic analysis of FDA-approved anticancer drugs

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Scaffold Searching of FDA and EMA-Approved Drugs Identifies Lead Candidates for Drug Repurposing in Alzheimer’s Disease

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Time of origin

Other Objects (12)

Repurposing FDA-approved drugs for anti-aging therapies

Repurposing FDA‐Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease

Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus

Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans

Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer

Computational prognostic evaluation of Alzheimer’s drugs from FDA-approved database through structural conformational dynamics and drug repositioning approaches

Repurposing of approved cardiovascular drugs

Single-cell-led drug repurposing for Alzheimer’s disease

In silico repurposing of antipsychotic drugs for Alzheimer’s disease

Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells

The First FDA-Approved Antibody-Drug Conjugate

A systematic analysis of FDA-approved anticancer drugs

Repurposing FDA-approved drugs for anti-aging therapies

Repurposing FDA‐Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease

Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus

Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans

Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer

Computational prognostic evaluation of Alzheimer’s drugs from FDA-approved database through structural conformational dynamics and drug repositioning approaches

Repurposing of approved cardiovascular drugs

Single-cell-led drug repurposing for Alzheimer’s disease

In silico repurposing of antipsychotic drugs for Alzheimer’s disease

Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells

The First FDA-Approved Antibody-Drug Conjugate

A systematic analysis of FDA-approved anticancer drugs

Repurposing FDA-approved drugs for anti-aging therapies

Repurposing FDA‐Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease

Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus

Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans

Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer

Computational prognostic evaluation of Alzheimer’s drugs from FDA-approved database through structural conformational dynamics and drug repositioning approaches

Repurposing of approved cardiovascular drugs

Single-cell-led drug repurposing for Alzheimer’s disease

In silico repurposing of antipsychotic drugs for Alzheimer’s disease

Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells

The First FDA-Approved Antibody-Drug Conjugate

A systematic analysis of FDA-approved anticancer drugs

Related objects

Reset password